Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151814 · ClinicalTrials.gov registry record · Phase 1
Olmesartan Pediatric Pharmacokinetic (PK) Study
A Phase 1 study of Hypertension, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 5
- Study locations
NCT00151814: Completed Phase 1 study of Hypertension, sponsored by Daiichi Sankyo.
NCT00151814 is a Phase 1 study of Hypertension that has completed, run by Daiichi Sankyo. The registered enrollment target is 24 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00151814, a Phase 1 study of Hypertension, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 5
- Study locations
Study Summary
Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
Conditions Studied
Interventions
- DRUG Olmesartan medoxomil
Study Locations (5)
Arkansas
- - Little Rock
California
- - La Jolla
Kentucky
- - Louisville
Missouri
- - Kansas City
Ohio
- - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
What the finished NCT00151814 record still lists
NCT00151814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Olmesartan medoxomil is the first listed.
NCT00151814 lists 5 locations in 5 states (Arkansas, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00151814 about?
NCT00151814 is a clinical study titled "Olmesartan Pediatric Pharmacokinetic (PK) Study". Determine single dose pharmacokinetic parameters of olmesartan in pediatric patients with hypertension in ages 12 months - 16 years
What is the current status of trial NCT00151814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-09. Estimated completion is 2008-02.
What conditions does trial NCT00151814 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00151814?
The interventions under investigation include: Olmesartan medoxomil (DRUG).
Who is sponsoring clinical trial NCT00151814?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00151814 being conducted?
This trial has 5 study locations across Arkansas, California, Kentucky, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00151814's enrollment target sits among peer trials
24 429th of 470 higher than 38 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
-
Sympathetic Mechanisms in Obesity-Crossover Design
RECRUITING · Phase 1
-
Targeting Endoplasmic Reticulum Stress in Human Hypertension
RECRUITING · Phase 1
-
: Vascular Function in Health and Disease
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia